Targeted Oncology interviews feature the world's leading oncologists sharing their insights on the latest news and advances in diagnostic testing, biomarkers, pathways, immunotherapy, and targeted therapeutics for better application into clinical practice.

Pralsetinib Shows Positive Phase 1/2 Results in RET Fusion+ NSCLC

November 26, 2022

Updated analysis from the phase 1/2 ARROW study evaluating pralsetinib in patients with RET fusion-positive non–small cell lung cancer showed the agent to be well tolerated and to elicit clinical activity at a dose of 400 mg daily.

Understanding Recent Developments in Mantle Cell Lymphoma

November 23, 2022

In an interview with Targeted Oncology, Jia Ruan, MD, PhD, discussed the updates in the mantle cell lymphoma space, including understanding molecular pathogenesis and risk stratification for this patient population.